Demographic, Payer, and Clinical Characteristics of Patients Receiving Bevacizumab (BEV) And Ranibizumab (RAN) For Treatment of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)
Abstract
Authors
J Chung J Radtchenko D Nero C Nabhan J Kish B Feinberg